We're now offering At-Home Monoclonal Antibody Therapy!

Appointments are on a first-come-first-serve basis.

Book your appointment with us now!

BEBTELOVIMAB and SOTROVIMAB (GLAXOSMITHKLINE) ➟ Call for pricing

The Department of Health and State of New Jersey has allocated IV Elements Monoclonal Antibodies and we are offering BEBTELOVIMAB and SOTROVIMAB (GlaxoSmithKline).

 
WHEN TO DRIP.

  • Tested positive for COVID-19 within 7 days and at high risk of getting more severe COVID-19, including hospitalization or death

  • Prophylaxis for those with exposure to COVID-19

  • Tested positive for COVID-19 within 7 days and considered high-risk with one of the following medical conditions:

    • Age 65 years or older

    • Obesity

    • Chronic kidney disease

    • Diabetes

    • Pregnancy

    • Suppressed immune system

    • Cardiovascular disease

    • Chronic lung diseases

    • Sickle cell disease

    • Neurodevelopmental disorders

    • Medical-related technological dependence

    • Down syndrome

    • Dementia

    • History of stroke

    • History of cerebrovascular disease

    • Immunosuppressive disease or immunosuppressive treatment

    • Current or former smoker

BENEFITS OF THIS DRIP.

  • Reduces amount of the SARS-CoV-2 virus in individual's system

  • Helps individuals feel better faster and have fewer days with COVID-19 symptoms

  • Prevents individuals from being hospitalized

ELEGIBILITY OF THIS DRIP.

  • BEBTELOVIMAB → Individuals 18 years and older who weigh at least 88lbs (40kg)

  • SOTROVIMAB → Individuals 65 years and older who weigh at least 88lbs (40kg)

  • Individuals who tested positive for COVID-19 within 7 days, but are not hospitalized

  • Individuals vaccinated or unvaccinated

WHAT IS BEBTELOVIMAB and SOTROVIMAB (GlaxoSmithKline)?

BEBTELOVIMAB is an investigational medicine used in adults 18 years of age and older who weigh at least 88 pounds (40kg), who are at high risk for severe COVID-19 — including hospitalization or death — for the treatment of mild to moderate symptoms of COVID-19 or post-exposure prophylaxis of COVID-19.

SOTROVIMAB (GlaxoSmithKline) is an investigational medicine used in adults 65 years of age and older who weigh at least 88 pounds (40kg), who are at high risk for severe COVID-19 — including hospitalization or death — for the treatment of mild to moderate symptoms of COVID-19 or post-exposure prophylaxis of COVID-19.

WHAT CAN I EXPECT FROM THE TREATMENT?

Monoclonal Antibody Therapy (mAb) treatment is given through an intravenous (IV) infusion. Depending on the mAb treatment you receive, the whole process takes about 30 - 90 minutes.

First, our medical staff will conduct a screening; then they start an IV, which delivers the mAbs to your body in about 30 minutes. Afterward, the medical staff will stay with you for another hour to be sure you aren’t having an allergic reaction or other side effects. These reactions are rare, but our staff must observe you for this hour.

It’s important to know that even if you start feeling better, you could still spread the virus for a while. So, you’ll need to isolate yourself (be alone) until all of these things happen:

  1. At least 10 days have passed since your first symptoms of COVID-19

  2. You haven’t had a fever in at least 24 hours, without taking any medicine that reduces fever

  3. Your other symptoms of COVID-19 are improving

IMPORTANT: Follow your healthcare provider’s instructions. Your personal health history may require you to meet additional conditions. Also, if you start to feel worse, don’t hesitate to seek medical care.

WHAT ARE THE SIDE EFFECTS?

  • Allergic reactions can happen during and after infusion. Tell your nurse right away if you get any of the following signs and symptoms of allergic reactions: Fever, chills, nausea, headache, shortness of breath, low or high blood pressure, rapid or slow heart rate, chest discomfort or pain, weakness, confusion, feeling tired, wheezing, swelling of your lips, face, or throat, rash including hives, itching, muscle aches, feeling faint, dizziness and sweating. These reactions may be severe or life threatening.

  • You may experience new or worsening symptoms after infusion, including fever, difficulty breathing, rapid or slow heart rate, tiredness, weakness or confusion. If these symptoms occur, contact your healthcare provider or seek immediate medical attention as some of these symptoms have required hospitalization. It is unknown if these symptoms are related to treatment or are due to the progression of COVID-19.

  • The side effects of getting any medicine by vein may include brief pain, bleeding, bruising of the skin, soreness, swelling, and possible infection at the infusion site. The side effects of getting any medicine by subcutaneous injection may include pain, bruising of the skin, soreness, swelling, and possible infection at the injection site.